GLP-1
| 4 min read
Positive results for GLP-1 drugs in alcohol use disorder, a new collaboration to advance in vivo CAR T therapies, Phase 3 readouts in oncology, rare disease, and vitiligo, and more led the news this week.
| 3 min read
It’s long been recognized that obesity in midlife significantly raises the risk of Alzheimer’s disease. A new study shows the biological mechanisms that contribute to pathogenesis.
| 4 min read
FDA leadership changes, pharma deals, clinical trials, and more led the news this week.
| 6 min read
Millions of patients are now taking drugs like Ozempic and Wegovy, but clinicians still struggle to predict who will benefit and how best to support lasting results.
| 4 min read
Eli Lilly’s oral orforglipron and Novo Nordisk’s higher-dose WeGovy could be approved on an extremely accelerated timeline.
| 3 min read
Novo Nordisk’s Phase 3 trials revealed that oral semaglutide failed to slow the progression of disease.
| 5 min read
Explore the mechanisms, clinical applications, and future opportunities of GLP-1 receptor agonists in drug development and disease management.
| 4 min read
Positive results for breast cancer, funding for precision therapies for heart disease, strong results for Lilly’s oral GLP-1, and more led the news this week.
| 7 min read
With blockbuster status secured, GLP-1 therapies face new questions about efficacy, delivery, and their role in treating multiple chronic diseases.
| 2 min read
Researchers showed that in rodent models, a glia-produced molecule could regulate weight loss and glucose metabolism without gastrointestinal symptoms.
